
Cancer genomic testing – Debbie Rhea’s story
Learn about the importance of genomic testing in treating cancer, and hear from patient; Debbie Rhea about the real-world impact it can have.
moreLearn about the importance of genomic testing in treating cancer, and hear from patient; Jamal Tamer about the real-world impact it can have.
moreOur organisation has more than 2,200 scientists at seven Roche Innovation Centers spanning each major continent
moreKathy Hyde hopes that telling her son’s story will help increase understanding of the challenges faced by individuals with autism spectrum disorder.
moreCaring for people with Alzheimer’s disease has a huge economic and emotional impact. Learn about the intangible costs and Freeha’s experience with her father.
moreLevi Garraway has officially started his new leadership role as Roche’s chief medical officer. Read Garraway’s story.
moreAll you need to know about the people and the important work at Roche Pharma Research and Early Development (pRED) Oncology as we discover the future in cancer care.
moreHCC is known as a ‘silent killer’ as the symptoms often appear too late for curative treatments. Learn more about the signs, symptoms and risk factors.
moreNeuromyelitis optica spectrum disorder (NMOSD) is a rare, lifelong and debilitating autoimmune disease of the central nervous system (CNS) that primarily damages the optic nerve and the spinal cord.
moreHeart failure affects millions of people and despite improvement in care, management remains challenging. Biomarkers can help patients at every stage of care.
moreThe liver is your body’s chemical processing plant, a powerhouse crucial to remove toxins; but liver cancer is on the rise. Learn what we can do to change this.
moreFind out more about haemophilia A and how Roche is developing novel approaches to hopefully advance the management of this serious disorder.
moreWe’re partnering with many different stakeholders to find the most effective way for the immune system to identify and kill cancer cells.
moreAdvanced analytics provide novel insights that could help to tackle some of the most complex problems in healthcare.
moreInsights on how personalised healthcare can bring meaningful benefits to patients with retinal diseases
moreThe promise of personalised healthcare is a simple one: finding the right treatment for every patient. Through strategic partnerships, Roche is committed to fulfilling that promise.
moreDr Gallia Levy, Associate Group Medical Director at Roche, shares her perspective on the need for sustained bleeding protection in haemophilia A.
moreLearn about haemophilia A through the eyes of patients, caregivers and experts.
moreIt is truly a diversified environment. From the interdisciplinary education to the multi-cultural workforce, I strongly believe our collective experiences and passion will drive the innovation engine to develop the next meaningful diagnostics solution for patients.
moreExplore how the patient pathway for people living with relapsing MS has changed over the past 20 years.
moreAs multidrug resistant strains of bacteria are posing a growing threat to human health worldwide, our scientists are working hard on the next generation of antibiotics and diagnostic tests.
moreHow does understanding each lung cancer’s unique footprint set you on the right path for a promising new future? Find out...
moreDiscover how we are advancing towards treatments that can stop, slow or prevent, and ultimately improve the care available for people with Alzheimer’s disease.
moreThe underlying biology of multiple sclerosis is similar for everyone, but its course and symptoms vary from person to person. Explore the similarities and differences between two forms of MS.
moreRoche and British biotechnology company Discuva are collaborating to develop new classes of antibiotics for the treatment of multidrug-resistant bacteria.
moreMost people can spend their entire lives not knowing they’ve been infected with CMV. But for transplant patients, this quiet invader can be life-threatening
moreWith today's health challenges, medical progress is more important than ever. Therapeutic antibodies are addressing the complexity of targeting diseases with unmet medical need.
moreApproximately 1.8 million people develop lung cancer every year. Can new diagnostic tools deliver earlier diagnosis and smarter treatment choices?
morePartnering builds on our culture, one in which we listen to a potential partner and structure a collaboration that meets both parties’ needs.
moreClinical trials are essential to providing the scientific data to determine whether new drugs, diagnostics or procedures are both safe and effective when used to diagnose and treat people. But how exactly do they work?
Securing safe blood supplies in the face of the Zika virus international health emergency
moreThe chart measuring visual acuity is the most popular poster in history.
moreA journey of discovery and diagnosis; looking back at the history of multiple sclerosis
moreThe partnership between Roche and Foundation Medicine, Inc. heralds a new chapter in the use of molecular information to choose the right treatments for cancer patients
moreAn innovative blood test known as a liquid biopsy could spare lung cancer patients from the ordeal of surgical biopsies.
moreAdvances in our knowledge of molecular biology and new technologies could redefine approaches to scientific research and individualised patient care for cancer. However, the complexity of treating this disease will grow in tandem. Here we describe the challenges we face and some of the approaches we are adopting to overcome them.
moreA select group of top scientists and researchers will meet to share their expertise in quantitative systems pharmacology.
moreInteresting facts about the world’s biggest health challenge.
moreRoche once again has a major presence at this years ASCO Annual Meeting, while also looking to the science and technologies that will hopefully bring us tomorrow's new therapeutic approaches
moreAdvances in our knowledge of molecular biology and new technologies could redefine approaches to scientific research and individualised patient care for cancer. However, the complexity of treating this disease will grow in tandem. Here we describe the challenges we face and some of the approaches we are adopting to overcome them.
moreOver the last 15 years, our knowledge of breast cancer has evolved. Availability of targeted treatments and diagnostics has substantially improved the survival for patients with advanced breast cancer.
moreWhile deoxyribonucleic acid, or DNA, is at the core of all created life, recombinant DNA technology was the groundbreaking technology at the origin of Genentech, one of the first biotech companies in the world, founded in 1976.
moreThis week, an expected 7,500 breast cancer clinicians and researchers from 90 countries will converge on San Antonio, Texas, for the 38th Annual San Antonio Breast Cancer Symposium (SABCS), the worlds largest breast cancer congress.
moreThe World Cancer Congress (WCC) is an important event for anyone involved in cancer control.
moreIn modern medicine, it is surprising to find that some diagnostic technologies are stuck in the 1970s. In the anatomic pathology lab, outdated processes can expose technicians and patients to potential dangers including tissue cross contamination and misdiagnosis.
moreRoche experts have developed a patented method for enzyme production. It enhances the production process for therapeutic antibodies.
moreCancer is a complex disease that begins when abnormal cells in any part of the body start to grow out of control, forming tumors that behave almost like new organs with their own immune cells and blood vessels.
moreAlzheimers disease, the most common form of dementia, can destroy memory and thinking skills as the condition progresses.
moreIt has been a busy time in the world of biosimilars. While regulatory bodies are getting their heads around developing clear-cut rules to ensure the safe introduction of biosimilar monoclonal antibodies, some countries are already seeing the first of these medicines enter the market.
moreMore than 500 colleagues from around the world participated in this inaugural fair held at the Mannheim site in mid-May.
more